| 1 |
33063648 | Molecular dynamic mechanism(s) of inhibition of bioactive antiviral phytochemical compounds targeting cytochrome P450 3A4 and P-glycoprotein. | 2022 Feb |
1 |
| 2 |
34949673 | Long Noncoding RNAs Hepatocyte Nuclear Factor 4A Antisense RNA 1 and Hepatocyte Nuclear Factor 1A Antisense RNA 1 Are Involved in Ritonavir-Induced Cytotoxicity in Hepatoma Cells. | 2022 May |
4 |
| 3 |
35138967 | Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case Report. | 2022 Feb 9 |
1 |
| 4 |
35153195 | Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans. | 2022 May |
2 |
| 5 |
35305258 | Nirmatrelvir Plus Ritonavir: First Approval. | 2022 Apr |
1 |
| 6 |
35347032 | Combined Use of Calcium-channel Blockers With Ombitasvir/Paritaprevir/Ritonavir Exacerbates Peripheral Edema in Elderly Japanese Patients. | 2022 Apr |
3 |
| 7 |
35352280 | Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib. | 2022 Apr |
2 |
| 8 |
35429391 | Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. | 2022 Apr 16 |
1 |
| 9 |
35486324 | A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates. | 2022 Apr 29 |
6 |
| 10 |
35567754 | Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. | 2022 May 14 |
1 |
| 11 |
33269470 | Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: A physiologically based pharmacokinetic/pharmacodynamic analysis. | 2021 Jul |
4 |
| 12 |
33467005 | Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength. | 2021 Jan 16 |
2 |
| 13 |
33513992 | Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells. | 2021 Jan 27 |
1 |
| 14 |
33629924 | Severe hyperkalaemia due to a potential drug-drug interaction between eplerenone and antiretrovirals in a HIV-positive patient after a myocardial infarction. | 2021 Jul |
2 |
| 15 |
33649517 | Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir. | 2021 Jun |
1 |
| 16 |
33821626 | Inhibition of CYP3A7 DHEA-S Oxidation by Lopinavir and Ritonavir: An Alternative Mechanism for Adrenal Impairment in HIV Antiretroviral-Treated Neonates. | 2021 Apr 19 |
1 |
| 17 |
34006500 | Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls. | 2021 Sep |
1 |
| 18 |
34139548 | Recombinant expression and characterization of novel P450s from Actinosynnema mirum. | 2021 Jul 15 |
1 |
| 19 |
34426442 | Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. | 2021 Nov 1 |
1 |
| 20 |
34848452 | The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells. | 2021 Dec |
1 |
| 21 |
31735989 | Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions. | 2020 May |
1 |
| 22 |
32044230 | An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4. | 2020 Mar 15 |
3 |
| 23 |
32140912 | Hypothalamic-pituitary-adrenal axis suppression by inhaled or nasal corticosteroids in HIV-infected patients. | 2020 Apr |
1 |
| 24 |
32427480 | Biopharmaceutic In Vitro In Vivo Extrapolation (IVIV_E) Informed Physiologically-Based Pharmacokinetic Model of Ritonavir Norvir Tablet Absorption in Humans Under Fasted and Fed State Conditions. | 2020 Jul 6 |
1 |
| 25 |
32557601 | Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling. | 2020 Sep |
1 |
| 26 |
32725720 | No relation between docetaxel administration route and high-grade diarrhea incidence. | 2020 Aug |
1 |
| 27 |
33244500 | RAPID DEVELOPMENT OF IATROGENIC CUSHING SYNDROME IN A PATIENT ON RITONAVIR: THE ADVERSE METABOLIC CONSEQUENCE OF TOPICAL STEROID USE. | 2020 Nov-Dec |
1 |
| 28 |
29696643 | Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. | 2019 Jan |
1 |
| 29 |
30660696 | Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. | 2019 Mar |
1 |
| 30 |
30783000 | Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions. | 2019 May |
1 |
| 31 |
30912932 | Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4. | 2019 Apr 16 |
2 |
| 32 |
30926609 | Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4. | 2019 May 17 |
5 |
| 33 |
31456404 | Conformational Response of N-Terminally Truncated Cytochrome P450 3A4 to Ligand Binding in Solution. | 2019 Sep 17 |
1 |
| 34 |
29232137 | Inhibition of Human CYP3A4 by Rationally Designed Ritonavir-Like Compounds: Impact and Interplay of the Side Group Functionalities. | 2018 Jan 2 |
3 |
| 35 |
29302721 | Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. | 2018 Apr |
6 |
| 36 |
29427135 | Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. | 2018 Jun |
3 |
| 37 |
29451681 | Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates. | 2018 Mar |
8 |
| 38 |
29634071 | [<p>One steroid injection in combination with HIV-medication resulted in a total adrenal insufficiency</p>]. | 2018 Apr 5 |
1 |
| 39 |
29851709 | Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety. | 2018 Aug |
1 |
| 40 |
29869311 | Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet. | 2018 Jul |
1 |
| 41 |
30044899 | Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers. | 2018 Nov |
3 |
| 42 |
28038962 | Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. | 2017 Feb |
1 |
| 43 |
28060049 | Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent With HIV-1 Infection. | 2017 May |
1 |
| 44 |
28341759 | A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. | 2017 May |
3 |
| 45 |
28403692 | Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. | 2017 Oct |
1 |
| 46 |
28458904 | Fluticasone furoate induced iatrogenic Cushing syndrome in a pediatric patient receiving anti-retroviral therapy. | 2017 |
1 |
| 47 |
28483778 | Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir. | 2017 Jul |
2 |
| 48 |
28960344 | Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat. | 2017 Dec |
4 |
| 49 |
29062559 | Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate: Case report. | 2017 Aug |
3 |
| 50 |
29108449 | Iatrogenic Cushing Syndrome in a 47-Year-Old HIV-Positive Woman on Ritonavir and Inhaled Budesonide. | 2017 Nov/Dec |
5 |